Dexramed

Global Clinical Development · Oncology · Strategic Advisory

Advancing global clinical development from first-in-human to regulatory approval.

Dexramed is the consulting practice of Olusoga Sylvester Osinowo, two decades leading complex, global Phase I–IV programs across oncology, infectious diseases, and digital therapeutics for the world's most demanding sponsors.

Start a conversation See career highlights →

Programs delivered for

Merck & Co.Boehringer IngelheimSIGA TechnologiesNektar TherapeuticsGates MRITakedaKyowa KirinCelgene
Clinical data review

About the Founder

A consulting practice built on the trials, not the slide deck.

Olusoga Sylvester Osinowo is a global clinical development leader with over twenty years across pharmaceutical companies, CROs, and biotechnology organizations. His career includes leadership roles at Merck & Co., Boehringer Ingelheim, PPD, and Theradex Oncology, and hands-on delivery of programs that have reached regulatory approval.

Through Dexramed LLC, he partners with sponsors and CROs as an embedded extension of their team, direct, accountable, and measured on milestones delivered. Recent engagements include CE3, HUTCHMED, Bavarian Nordic, and Avoca.

20+

Years in clinical development

I–IV

Phase coverage

Global

Multi-region programs

2019

PPD CEO 'Will to Win'

Career Highlights

Programs that reached patients.

Selected work across global oncology trials, immunotherapy combinations, digital therapeutics, and operational turnarounds, the kind of execution that moves regulatory submissions and patient outcomes forward.

Regulatory Impact

KEYNOTE-224, FDA approval of Keytruda in advanced HCC

Led the global Phase II study in hepatocellular carcinoma that contributed to Pembrolizumab's FDA approval for advanced HCC.

Immuno-Oncology

Merck's first triplet immunotherapy combination in HCC

Spearheaded the Pembrolizumab + MK1308 + Lenvatinib combination program, a first for Merck Oncology.

Global Phase III

MK7902-012, Pembrolizumab + Lenvatinib + TACE in unresectable HCC

Directed the global Phase III trial across complex multi-region operations and combination-therapy logistics.

Operational Acceleration

50% enrollment acceleration, 24 months to 12

Boehringer Ingelheim's first triplet Phase Ib in recurrent/metastatic HNSCC (BI 770371 + Pembrolizumab ± Cetuximab).

Digital Therapeutics

ENSPIRUS, global Phase III for CT-155 in schizophrenia

Managed a pioneering global digital therapeutic Phase III, advancing the operational playbook for digital health trials.

Recognition

PPD CEO 'Will to Win' Award · 2019

Recognized for exceptional leadership and performance across global clinical operations.

Leadership Experience

Two decades inside the rooms where programs are run.

Tenure

Merck & Co.

Global Clinical Trial Leadership · Phase II–III Oncology

  • Regulatory strategy and FDA approval support
  • Immuno-oncology and hepatocellular carcinoma expertise
  • Cross-functional leadership across global teams
Tenure

Boehringer Ingelheim

Global Clinical Trial Leadership · Oncology & Digital Therapeutics

  • Operational strategy and enrollment acceleration
  • Head & Neck cancer program leadership
  • First triplet combination Phase Ib in HNSCC
Tenure

PPD

Clinical Operations Leadership · Oncology, Vaccines, Infectious & Rare Diseases

  • Global project delivery and sponsor engagement
  • Enterprise-wide Veeva Vault migration
  • PPD CEO 'Will to Win' Award · 2019
Tenure

Theradex Oncology

NCI/CTEP Lead Auditor · CRA Manager · Clinical Project Manager

  • Children's Oncology Group Auditor
  • Led and mentored teams of 15–20 CRAs
  • Drove productivity, quality, and sponsor satisfaction

Therapeutic & Core Expertise

Depth across the areas where execution is hardest.

Oncology

  • Hepatocellular Carcinoma (HCC)
  • Head & Neck Squamous Cell Carcinoma
  • Renal Cell Carcinoma
  • Immuno-Oncology

Beyond Oncology

  • Digital Therapeutics
  • Infectious Diseases
  • Vaccines
  • Respiratory Diseases
  • Schizophrenia
  • Rare Diseases

Core Capabilities

  • Global Clinical Operations
  • Regulatory Strategy (FDA & Global)
  • CRO & Vendor Management
  • Inspection Readiness
  • Program & Portfolio Management

Consulting Services

Where Dexramed plugs in.

Senior support across the full development lifecycle, from study startup and rescue to regulatory readiness and CRO governance.

Clinical Trial Leadership

Senior trial leadership across Phase I–IV programs, accountable for protocol execution, milestones, and the decisions that move assets forward.

Study Rescue & Turnaround

Diagnose stalled studies, restructure operations, and return programs to predictable delivery, proven across global oncology and digital therapeutic trials.

Inspection Readiness

FDA and global inspection preparation built on first-hand audit experience, calm, evidence-led, and grounded in regulatory reality.

CRO & Vendor Oversight

Vendor selection, governance, and performance frameworks that turn CRO relationships into measurable advantage instead of friction.

Site Management Optimization

Therapeutic-area site intelligence and enrollment acceleration, including programs delivered on 50% compressed timelines.

Clinical Development Strategy

First-in-human through approval: development planning shaped by two decades of oncology, infectious disease, and digital therapeutic programs.

Why Dexramed

Senior counsel, embedded where decisions are made.

We choose engagements where our experience compounds your team's, and we measure ourselves on what gets shipped.

20+

Years leading clinical research and drug development

Phase I–IV

Hands-on delivery across the full trial lifecycle

Global

Programs delivered for Merck, BI, PPD, and biotech innovators

FDA-Approved

Direct contribution to Keytruda's HCC approval

Research Partners

Worked alongside world-leading research institutions.

Site partnerships and investigator relationships built across two decades of global oncology trial delivery.

  • MD Anderson Cancer Center
  • Memorial Sloan Kettering
  • Princess Margaret Cancer Centre
  • Mount Sinai
  • Columbia University
  • Mayo Clinic
  • Moffitt Cancer Center

Clients

Trusted by teams whose timelines matter.

"
Dexramed restructured our Phase II program in weeks. Their operational insight cut six months off our enrollment runway.

VP, Clinical Operations

Mid-cap Biotech

"
Olusoga's regulatory instincts are exceptional. He sees the question behind the question, the kind of advisor you want in the room before a milestone meeting.

Chief Medical Officer

Specialty Pharma

"
We brought Dexramed in to oversee a struggling CRO engagement. Within a quarter, governance, quality, and timelines were back on track.

Head of Development

Global CRO

Let's build the future of clinical research

Deliver operational excellence. Accelerate timelines. Bring life-changing therapies to patients, faster.

Start a conversation

Contact

Let's discuss your program.

Tell us where your trial stands and what you're trying to unlock. We respond within two business days.

  • info@dexramed.com
  • +1 (908) 342 4448
  • Global · Headquartered remotely